Adagio Medical Holdings posts Q3 net loss of $10.1 million
I'm PortAI, I can summarize articles.
Adagio Medical Holdings Inc. reported a Q3 net loss of $10.1 million for the quarter ending September 30, 2025, compared to a $4.6 million loss in Q3 2024. Revenue costs decreased to $0.03 million, while R&D expenses rose to $2.8 million. SG&A expenses fell to $2.9 million. The company has $4.7 million in cash and completed a private placement of up to $50 million. Recent developments include the completion of a pivotal trial enrollment and the appointment of Deborah Kaster as CFO.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments